Sheet 4 of PTO-1449 dated 7/16/03 (rescanned)

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number 5405-232DV	Serial No. 09/384,749
	Applicants: Amalfitano et al.	
	Filing Date: Concurrently herewith	Group: Unknown

		63	Hardy et al.: Construction of Adenovirus Vectors through Cre-*lox* Recombination, *Journal Of Virology*, 71:3, 1842-1849 (1997)
		64	Hartigan-O'Connor et al.: Increased Efficiency Of Gutted Adenovirus Production In Cells Expressing Preterminal Protein and DNA Polymerase, American Society of Gene Therapy *Adenoviruses*, Abstract #703 (1998)
		65	Hartigan-O'Connor et al.: Improved Production of Gutted Adenovirus in Cells Expressing Adenovirus Preterminal Protein and DNA Polymerase, *Journal Of Virology*, 73:9, 7835-7841 (1999)
		66	Hauser et al.: *Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy*, Neuromuscular Disorders 7, 277-283 (1997)
		67	He et al.: A simplified system for generating recombinant adenoviruses, *Proc. Natl. Acad. Sci. USA*, 95, 2509-2514 (1998)
		68	Hermans et al.: man lysosomal α-glucosidase: functional characterization of the cosylation sites, *M.J.*, 289, 681-686 (1993)
		69	Hoefsloot et al.: Primary structure and processing of lysosomal α-glucosidase; homology with the intestinal sucrase – isomaltase complex, *The EMBO Journal*, 7:6, 1697-1704 (1988)
		70	Hoefsloot et al.: Expression and routeing of human lysosomal α-glucosidase in transiently transfected mammalian cells, *Biochem. J.*, 272 485-492 (1990)
		71	Hu et al.: Persistence of an [E1⁻, Polymerase⁻] Adenovirus Vector Despite Transduction of a Neoantigen into Immune-Competent Mice, *Human Gene Therapy* 10, 355-364 (1999)
		72	Ilan et al.: Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression, *Proc. Natl. Acad. Sci. USA*, 94, 2587-2592 (1997)
		73	International Search Report; PCT/US99/19540, 1999.
		74	Jones et al.: Isolation of Deletion and Substitution Mutants of Adenovirus Type 5, *Cell*, 13, 181-188 (1978)
		75	Kaplan et al.: Characterization of Factors Involved in Modulating Persistence of Transgene Expression from Recombinant Adenovirus in the Mouse Lung, *Human Gene Therapy*, 8, 45-56 (1997)
		76	Kochanek et al.: A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophic and β-galactosidase, *Proc. Natl. Acad. Sci. USA*, 93, 5731-5736 (1996)
		77	Krougliak et al.: Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants, *Human Gene Therapy*, 6 1575-1586 (1995)
		78	Kumar-Singh et al. "Encapsidated adenovirus minichromosomes as gene-delivery vehicles," *American Journal of Human Genetics*. 59:Suppl 4 page A202, ISSN: 0002-9297 (1996).
		79	Kumar-Singh et al.: Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells, *Human Molecular Genetics* 5:7, 913-921 (1996)
		80	Kumar-Singh et al.: Encapsidated adenovirus mini-chromosome-mediated delivery of genes to the retina: application to the rescue of photoreceptor degeneration, *Human Molecular Genetics* 7:12,

EXAMINER _____ DATE CONSIDERED 6/9/03

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.